The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis

Mast Cells Promote Airway Smooth Muscle Cell Differentiation via Autocrine Up-Regulation of TGF- 1

(2014) L. Woodman et al.   JOURNAL OF IMMUNOLOGY

The Intermediate Conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling

(2013) Dan Bi et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Activation of endothelial and epithelial KCa2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles

(2012) Christel Kroigaard et al.   BRITISH JOURNAL OF PHARMACOLOGY

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

(2011) Ganesh Raghu et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Functional KCa3.1 K+ channels are required for human fibrocyte migration

(2011) Glenn Cruse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Involvement of Dominant-negative Spliced Variants of the Intermediate Conductance Ca2+-activated K+Channel, KCa3.1, in Immune Function of Lymphoid Cells

(2011) Susumu Ohya et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Opening of Small and Intermediate Calcium-Activated Potassium Channels Induces Relaxation Mainly Mediated by Nitric-Oxide Release in Large Arteries and Endothelium-Derived Hyperpolarizing Factor in Small Arteries from Rat

(2011) E. Stankevicius et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Therapeutic potential of KCa3.1 blockers: recent advances and promising trends

(2010) Heike Wulff et al.   Expert Review of Clinical Pharmacology

Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels

(2009) I. Grgic et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia

(2008) K. I. Ataga et al.   BLOOD